Compare Fidelity National Information Servcs Inc (FIS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Medpace Holdings Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.19 (market cap $17.71B), while Medpace Holdings Inc trades at $613.77 (market cap $16.82B). The key difference: Fidelity National Information Servcs Inc and Medpace Holdings Inc are close in size by market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Medpace Holdings Inc for 14 Days on average.
| FIS | MEDP | |
|---|---|---|
Market Cap | $17.71B | $16.82B |
Volume | 9,047,825 | 223,093 |
Sector | Technology | Health |
52-Week High | $68.57 | $630.19 |
52-Week Low | $32.44 | $393.42 |
Typical Hold Time | 88 Days | 14 Days |
Enterprise Value | $38.22B | $16.44B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $33.82, up 1.2% today, with a bearish technical signal despite beating earnings estimates in two of the last three quarters. The stock shows attractive valuation metrics with a P/E of 5.27 and P/S of 1.46, while analyst consensus remains strongly bullish with a $47.15 price target. Recent business developments include multiple core banking platform wins and new embedded banking offerings, signaling growth momentum in financial technology services.
The outlook appears positive given FIS's improving profitability trajectory and strong analyst support, though investors should monitor debt levels and execution risks. With revenue projected to grow to $12.2B in 2026 and net income margin expanding to 27.64%, the stock offers fundamental upside potential if the company can maintain its competitive positioning in banking technology modernization.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
